174 related articles for article (PubMed ID: 31394026)
21. Computational determination of hERG-related cardiotoxicity of drug candidates.
Lee HM; Yu MS; Kazmi SR; Oh SY; Rhee KH; Bae MA; Lee BH; Shin DS; Oh KS; Ceong H; Lee D; Na D
BMC Bioinformatics; 2019 May; 20(Suppl 10):250. PubMed ID: 31138104
[TBL] [Abstract][Full Text] [Related]
22. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
23. In silico prediction of hERG inhibition.
Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
[TBL] [Abstract][Full Text] [Related]
24. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
25. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Zachariae U; Giordanetto F; Leach AG
J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
[TBL] [Abstract][Full Text] [Related]
26. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
27. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
Leong MK
Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
[TBL] [Abstract][Full Text] [Related]
28. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
[TBL] [Abstract][Full Text] [Related]
29. The interactions between hERG potassium channel and blockers.
Du L; Li M; You Q
Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
[TBL] [Abstract][Full Text] [Related]
30. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
[TBL] [Abstract][Full Text] [Related]
31. TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction.
Meng J; Zhang L; Wang L; Li S; Xie D; Zhang Y; Liu H
Toxicology; 2021 Dec; 464():153018. PubMed ID: 34757159
[TBL] [Abstract][Full Text] [Related]
32. The Catch-22 of Predicting hERG Blockade Using Publicly Accessible Bioactivity Data.
Siramshetty VB; Chen Q; Devarakonda P; Preissner R
J Chem Inf Model; 2018 Jun; 58(6):1224-1233. PubMed ID: 29772901
[TBL] [Abstract][Full Text] [Related]
33. HergSPred: Accurate Classification of hERG Blockers/Nonblockers with Machine-Learning Models.
Zhang X; Mao J; Wei M; Qi Y; Zhang JZH
J Chem Inf Model; 2022 Apr; 62(8):1830-1839. PubMed ID: 35404051
[TBL] [Abstract][Full Text] [Related]
34. 3D-SDAR modeling of hERG potassium channel affinity: A case study in model design and toxicophore identification.
Stoyanova-Slavova IB; Slavov SH; Buzatu DA; Beger RD; Wilkes JG
J Mol Graph Model; 2017 Mar; 72():246-255. PubMed ID: 28129595
[TBL] [Abstract][Full Text] [Related]
35. Investigating cardiotoxicity related with hERG channel blockers using molecular fingerprints and graph attention mechanism.
Wang T; Sun J; Zhao Q
Comput Biol Med; 2023 Feb; 153():106464. PubMed ID: 36584603
[TBL] [Abstract][Full Text] [Related]
36. Development and evaluation of an in silico model for hERG binding.
Song M; Clark M
J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
[TBL] [Abstract][Full Text] [Related]
37. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
[TBL] [Abstract][Full Text] [Related]
38. Ligand structural aspects of hERG channel blockade.
Aronov AM
Curr Top Med Chem; 2008; 8(13):1113-27. PubMed ID: 18782007
[TBL] [Abstract][Full Text] [Related]
39. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds.
Nisius B; Göller AH; Bajorath J
Chem Biol Drug Des; 2009 Jan; 73(1):17-25. PubMed ID: 19152631
[TBL] [Abstract][Full Text] [Related]
40. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
Moorthy NS; Ramos MJ; Fernandes PA
SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
